ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Analyst Earnings Estimates
NASDAQ:ALNY - Nasdaq - US02043Q1076 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 844.3M 71.29% | 1.037B 22.87% | 1.828B 76.24% | 2.283B 24.87% | 2.706B 18.53% | 3.588B 32.59% | 4.43B 23.47% | 5.645B 27.43% | 6.658B 17.95% | 6.577B -1.22% | 7.499B 14.02% | |
| EBITDA YoY % growth | -661.1M 16.70% | -740.6M -12.03% | -228.121M 69.20% | -63.792M 72.04% | 162.2M 354.26% | 681.38M 320.09% | 2.77B 306.53% | 3.954B 42.74% | 5.76B 45.68% | 2.967B -48.49% | 3.476B 17.16% | |
| EBIT YoY % growth | -708.7M 14.45% | -785.1M -10.78% | -282.175M 64.06% | -121.411M 56.97% | -42.428M 65.05% | 441.9M 1,141.54% | 1.236B 179.70% | 2.209B 78.72% | 3.451B 56.22% | 2.635B -23.65% | 3.818B 44.90% | |
| Operating Margin | -83.94% | -75.68% | -15.43% | -5.32% | -1.57% | 12.32% | 27.90% | 39.13% | 51.83% | 40.06% | 50.91% | |
| EPS YoY % growth | -7.12 7.05% | -8.66 -21.63% | -3.56 58.89% | -2.05 42.55% | -1.25 38.82% | 2.58 306.13% | 8.90 245.19% | 13.91 56.20% | 19.90 43.07% | 20.79 4.51% | 24.53 17.96% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.63 42.69% | -0.70 -34.37% | -0.75 -475.12% | -0.47 45.72% | 0.06 110.25% | 0.02 102.92% | 0.18 124.56% | 0.75 259.83% | 0.82 1,163.22% |
| Revenue Q2Q % growth | 594.09M 35.11% | 567.4M 14.78% | 592.66M -10.18% | 675.17M 34.79% | 789.08M 32.82% | 792.9M 39.74% | 840.38M 41.80% | 963.63M 42.72% | 1.017B 28.88% |
| EBITDA Q2Q % growth | -80.985M -29.89% | -94.003M -214.20% | -93.146M -220.76% | -86.924M -152.67% | -70.115M 13.42% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -67.785M 41.77% | -93.567M -115.42% | -95.935M -297.34% | -40.897M 46.82% | -11.856M 82.51% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.87 -175.65% | -0.91 | 0.04 | 4.00% |
| Q2 2024 Q2Q % growth | -0.13 94.12% | -1.10 | 0.97 | 88.19% |
| Q1 2024 Q2Q % growth | -0.52 62.86% | -1.21 | 0.69 | 56.90% |
| Q4 2023 Q2Q % growth | -1.10 34.52% | -1.35 | 0.25 | 18.47% |
| Q3 2023 Q2Q % growth | 1.15 142.75% | -1.36 | 2.51 | 184.40% |
| Q2 2023 Q2Q % growth | -2.21 3.49% | -1.40 | -0.81 | -58.30% |
| Q1 2023 Q2Q % growth | -1.40 30.00% | -1.80 | 0.40 | 22.24% |
| Q4 2022 Q2Q % growth | -1.68 22.22% | -1.91 | 0.23 | 12.09% |
| Q3 2022 Q2Q % growth | -2.69 -64.02% | -1.78 | -0.91 | -51.47% |
| Q2 2022 Q2Q % growth | -2.29 -42.24% | -1.66 | -0.63 | -37.75% |
| Q1 2022 Q2Q % growth | -2.00 -16.96% | -1.88 | -0.12 | -6.57% |
| Q4 2021 Q2Q % growth | -2.16 -3.35% | -1.57 | -0.59 | -37.46% |
| Q3 2021 Q2Q % growth | -1.64 24.77% | -1.60 | -0.04 | -2.56% |
| Q2 2021 Q2Q % growth | -1.61 -3.21% | -1.65 | 0.04 | 2.16% |
| Q1 2021 Q2Q % growth | -1.71 6.56% | -1.76 | 0.05 | 3.03% |
| Q4 2020 Q2Q % growth | -2.09 18.68% | -1.74 | -0.35 | -19.89% |
| Q3 2020 Q2Q % growth | -2.18 -13.54% | -1.67 | -0.51 | -30.49% |
| Q2 2020 Q2Q % growth | -1.56 19.17% | -1.75 | 0.19 | 10.74% |
| Q1 2020 Q2Q % growth | -1.83 -5.78% | -1.92 | 0.09 | 4.60% |
| Q4 2019 Q2Q % growth | -2.57 | -2.25 | -0.32 | -14.15% |
| Q3 2019 Q2Q % growth | -1.92 | -2.08 | 0.16 | 7.55% |
| Q2 2019 Q2Q % growth | -1.93 | -1.88 | -0.05 | -2.54% |
| Q1 2019 Q2Q % growth | -1.73 | -2.11 | 0.38 | 18.04% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 500.919M -33.26% | 543.76M | -42.841M | -7.88% |
| Q2 2024 Q2Q % growth | 659.825M 107.00% | 452.99M | 206.835M | 45.66% |
| Q1 2024 Q2Q % growth | 494.333M 54.82% | 435.88M | 58.453M | 13.41% |
| Q4 2023 Q2Q % growth | 439.718M 31.26% | 451.75M | -12.032M | -2.66% |
| Q3 2023 Q2Q % growth | 750.53M 183.97% | 391.21M | 359.32M | 91.85% |
| Q2 2023 Q2Q % growth | 318.754M 41.79% | 357.52M | -38.766M | -10.84% |
| Q1 2023 Q2Q % growth | 319.29M 49.69% | 318.5M | 790K | 0.25% |
| Q4 2022 Q2Q % growth | 335M 29.59% | 319.4M | 15.6M | 4.88% |
| Q3 2022 Q2Q % growth | 264.3M 40.88% | 297.59M | -33.29M | -11.19% |
| Q2 2022 Q2Q % growth | 224.8M 1.90% | 261M | -36.2M | -13.87% |
| Q1 2022 Q2Q % growth | 213.3M 20.10% | 248.24M | -34.94M | -14.08% |
| Q4 2021 Q2Q % growth | 258.5M 58.01% | 238.3M | 20.2M | 8.48% |
| Q3 2021 Q2Q % growth | 187.6M 49.01% | 223.07M | -35.47M | -15.90% |
| Q2 2021 Q2Q % growth | 220.6M 112.12% | 196.66M | 23.94M | 12.17% |
| Q1 2021 Q2Q % growth | 177.6M 78.49% | 172.11M | 5.49M | 3.19% |
| Q4 2020 Q2Q % growth | 163.6M 128.17% | 149.74M | 13.86M | 9.26% |
| Q3 2020 Q2Q % growth | 125.9M 79.60% | 123.17M | 2.73M | 2.22% |
| Q2 2020 Q2Q % growth | 104M 132.66% | 101.47M | 2.53M | 2.49% |
| Q1 2020 Q2Q % growth | 99.5M 198.80% | 93.552M | 5.948M | 6.36% |
| Q4 2019 Q2Q % growth | 71.7M | 73.026M | -1.326M | -1.82% |
| Q3 2019 Q2Q % growth | 70.1M | 57.539M | 12.561M | 21.83% |
| Q2 2019 Q2Q % growth | 44.7M | 70.584M | -25.884M | -36.67% |
| Q1 2019 Q2Q % growth | 33.3M | 24.065M | 9.235M | 38.38% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 36.04% | 0% | 21.41% |
| Revenue | 0% | 19.22% | -0.17% | 0.4% |